Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index; none of the 57 sources its claims cite is checked for support yet.
Abstract
Human T cells modified with nucleic acids constitute a powerful and emerging therapeutic modality for cancer, autoimmune disorders, and aging-related diseases. However, delivering nucleic acids, such as mRNA encoding synthetic receptors, transcription factors, cytokines, or genome editors to T cells can be challenging, as nucleic acids can unintentionally reduce viable T cell yield and function, particularly when delivered sequentially ex vivo . To address this challenge, we evaluated the efficiency of serial non-viral delivery of synthetic mRNA encapsulated within lipid nanoparticles (LNPs) incorporating cationic lipid, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and fusogenic helper lipid, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). DOTAP/DOPE-containing LNPs delivered mRNA more efficiently than a clinically benchmarked 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)-containing LNP formulation, resulting in significantly higher protein expression in primary human T cells. Furthermore, DOTAP/DOPE-LNP delivery resulted in 100% higher yield of live cells compared to electroporation, an advantage that compounded over serial rounds, with LNP-treated cultures maintaining substantially more viable cells through all four transfections. Additionally, serial transfection of mRNAs encoding a therapeutically relevant chimeric antigen receptor (CAR) payload produced functional CAR T cells. These results demonstrate that LNPs can be a viable platform for serial and iterative T cell engineering using multiple mRNA payloads, providing an alternative to electroporation for the engineering of therapeutic T cells.
Overview
CoChat Summary
TL;DR
This study shows that DOTAP/DOPE-containing lipid nanoparticles (SM102-DD) can serially deliver mRNA to primary human T cells with higher viable cell yields than electroporation while producing functional uPAR CAR T cells. The platform preserves untransfected bystander cells across four rounds, though per-round transfection efficiency remains lower than electroporation.
Key findings
- SM102-DD LNPs (5% DOTAP + 5% DOPE) delivered reporter mRNA more efficiently than SM102-DSPC; replacing DSPC with 5% DOTAP gave 50-fold more transfected cell yield, and adding DOPE augmented this by 1.8-fold.
- Four serial transfections every 24 h maintained reporter expression and produced 100% higher live-cell yield than electroporation; LNP-treated cultures had significantly higher total viable cell number and more live untransfected cells across rounds.
- Uptake was primarily via macropinocytosis: EIPA and MβCD reduced eGFP MFI to 1,370 and 1,710 vs 4,483 untreated (~3-fold lower), while clathrin, dynamin, and caveolae inhibitors did not significantly reduce transfected cell yield.
- Serial uPAR CAR mRNA delivery produced functional CAR T cells: CAR surface MFI rose from 722 to 3,535 across 250–1,000 ng doses; target-cell killing was comparable to electroporation by 96 h, with higher CD69+CD25+ activation and IFN-γ vs mock, and exhaustion markers below 1.5%.
Methods
- In vitro primary human CD3+ T cells from healthy donors (16 donors total; typical n = 9, 3 donors), activated 48 h and cultured in ImmunoCult-XF + 100 IU/mL IL-2.
- LNPs formulated by vortex mixing with SM102, cholesterol, DMG-PEG2000, and DSPC/DOTAP/DOPE; characterized by DLS, RiboGreen, and zeta potential. Reporter mRNA (0.5 µg/500,000 cells) or uPAR CAR mRNA (2 µg/700,000 cells) was delivered every 24 h for four rounds and compared with Lonza 4D electroporation (EO115/CM138).
- Readouts: flow cytometry for expression/viability/phenotype, confocal imaging for uptake/lysosomal colocalization, Incucyte cytotoxicity, IFN-γ ELISA, and ANOVA.
Limitations
- Stated: LNP inflammatory responses were not evaluated; activation/exhaustion was assessed only at endpoint; longer-term persistence, memory differentiation, and functional durability need study; different mRNA doses/transcript lengths may affect viability/yield; donor variability requires larger diverse cohorts; assays did not fully distinguish electroporation-mediated death from CAR-dependent cytotoxicity.
- Stated: per-round LNP efficiency was lower than electroporation during the first two transfections; CAR-dependent effects were more robustly resolved in the electroporation arm, and LNP treatment may elevate PD-1+TIM-3+ independent of CAR.
- Evident: donors were not age- or sex-matched and donor number was not formally powered; LNPs were made by vortex mixing, which may yield larger/less uniform particles than microfluidic methods; data are available only upon request.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
0 Valid · 0 Not valid · 37 Not checked · 100 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall cell viability percentages over four transfections were statistically similar between LNP and electroporation-treated groups (Figures 6C and S5C).”
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > Four rounds of serial LNP-transfection yielded more viable T cells than serial electroporation
plainn = 12- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CAR was expressed and trafficked to the cell surface after each dose using the SM102-DD LNPs (Figure 7C).”
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > Serial delivery of uPAR CAR mRNA via LNPs produces functional CAR T cells
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The addition of DOTAP to LNP formulations enhanced the delivery of firefly luciferase (ffluc) and eGFP mRNA to T cells cultured in ImmunoCult-XF compared with the SM102-DSPC formulation or the commercially available transfection agent MessengerMAX (mmax).”
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > Titrating DOTAP in an LNP formulation improved mRNA delivery to primary human T cells ex vivo
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In T cells cultured in RPMI/10% FBS, both ffluc and eGFP expression were significantly reduced compared to T cells in serum-free ImmunoCult-XF when delivered using SM102-DD (Figures 3A, 3C, S3A, and S3C).”
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > LNP-mediated mRNA delivery to T cells depended on media conditions
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, this early advantage was offset by pronounced loss of total viable cells over the serial transfection course (Figure S5B).”
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > Four rounds of serial LNP-transfection yielded more viable T cells than serial electroporation
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
59 more claims
Create a free account to see all 137 claims and to verify the 57 references still open.
- It may state two separate claims as one. 46
- Probably not a substantial claim. 31
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > Titrating DOTAP in an LNP formulation improved mRNA delivery to primary human T cells ex vivo
“replacing DSPC with varying amounts of DOTAP from 5% to 40% by molar ratio, while proportionally decreasing cholesterol content”
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Materials and methods > LNP formulation and characterization
“the SM102-DOTAP5 LNP was made by replacing 5% DSPC with 5% cationic lipid DOTAP (Avanti Polar Lipids, Birmingham, AL, USA) and adding 5% to the molar ratio of cholesterol.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Discussion
“Donor-to-donor variability was observed across 16 donors for absolute yields of transfected cells (Figure 7H)”
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > Serial delivery of uPAR CAR mRNA via LNPs produces functional CAR T cells
“(H) Number of live CAR+ cells at each time point across SM102-DD-CAR and EO115-CAR conditions (n = 9, 3 donors).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Materials and methods > LNP formulation and characterization
“the SM102-DOTAP5 LNP was made by replacing 5% DSPC with 5% cationic lipid DOTAP”
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > Adding DOPE to DOTAP-containing LNP improved mRNA delivery to T cells
“SM102-DOTAP5 LNPs are composed of SM102, 5% DOTAP, cholesterol, and DMG-PEG2000.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > LNP-mediated mRNA delivery to T cells depended on media conditions
“SM102-DSPC LNPs exhibit consistent zeta potentials”
§ Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles > Results > LNP-mediated mRNA delivery to T cells depended on media conditions
“Both formulations cultured in RPMI/10% FBS showed a significant difference in zeta potential compared to ImmunoCult-XF”
Citations
Cites
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,227
Senolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
Dilliard, S. A., Cheng, Q., & Siegwart, D. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109256118 · Cited by 1,018 · cited 2×
“85 Adding helper lipid DOPE augmented the improvement in transfection by 1.8-fold, boosting both protein production and the number of transfected cells, possibly due to an increase in endosomal escape mediated by the fusogenic nature of DOPE.”
InfluentialRemote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
Research works printed but not linked: 1
- Metzloff, 2024, Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy (adv. Mater. 26/2024), Adv. Mater., 36
Cited by
Still being checked.
Metadata
- Authors
- Ramamurthy, A., Scimonelli, G., Murphy, W. L., & Saha, K.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Murphy, William L.
- Saha, Krishanu
- Venue
- Molecular Therapy Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2026-12
- Volume
- 37
- Issue
- 4
- Pages
- 103081
- ISSN
- 2162-2531 (ISSN-L)
- PMC
- PMC13634528
- OpenAlex
- W7206213539
- Cited by
- 0
- References
- 104
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Locations
- Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Science Foundation (EEC 1648035)
- National Institutes of Health (R01 CA278051, R35 GM119644)
- Wisconsin Alumni Research Foundation
- Office of the Vice Chancellor for Research and Graduate Education, University of Wisconsin-Madison
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- T cell engineering, lipid nanoparticles, mRNA delivery, cationic lipids, chimeric antigen receptor T cells, chimeric antigen receptor, T cell viability, non-viral gene delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles. https://app.cochat.ai/papers/10.1016/j.omtn.2026.103081
- The paper
- Ramamurthy, A., Scimonelli, G., Murphy, W. L., & Saha, K. (2026). Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles. Molecular Therapy Nucleic Acids. https://doi.org/10.1016/j.omtn.2026.103081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.